Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial

Barbagelata, Alejandro; Di Carli, Marcelo F.; Califf, Robert M.; Garg, Jyotsna; Birnbaum, Yochai; Grinfeld, Liliana; Gibbons, Raymond J.; Granger, Christopher B.; Goodman, Shaun G.; Wagner, Galen S.; Mahaffey, Kenneth W.; for the AMISTAD Investigators,

doi:10.1016/j.ahj.2004.10.014

« Previous Next »American Heart Journal
Volume 150, Issue 4 , Pages 659-665, October 2005

Electrocardiographic infarct size assessment after thrombolysis: Insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial

Alejandro Barbagelata, MD
- Hospital Italiano, Buenos Aires, Argentina
Marcelo F. Di Carli, MD
- Brigham and Women Hospital, Boston, Mass
Robert M. Califf, MD
- Duke Clinical Research Institute, Durham, NC
Jyotsna Garg, MS
- Duke Clinical Research Institute, Durham, NC
Yochai Birnbaum, MD
- University of Texas Medical Branch, Galveston, Tex
Liliana Grinfeld, MD
- Hospital Italiano, Buenos Aires, Argentina
Raymond J. Gibbons, MD
- Mayo Clinic, Rochester, Minn
Christopher B. Granger, MD
- Duke Clinical Research Institute, Durham, NC
Shaun G. Goodman, MD
- Canadian Heart Research Centre and Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Canada
Galen S. Wagner, MD
- Duke Clinical Research Institute, Durham, NC
- Reprints not available from the authors.
Kenneth W. Mahaffey, MD
- Duke Clinical Research Institute, Durham, NC
for the AMISTAD Investigators

Received 21 May 2004; accepted 13 October 2004.

Background

Noninvasive methods are needed to evaluate reperfusion success in patients with acute myocardial infarction (MI). The AMISTAD trial was analyzed to compare MI size and myocardial salvage determined by electrocardiogram (ECG) with technetium Tc 99m sestamibi single-photon emission computerized tomography (SPECT) imaging.

Methods

Of 236 patients enrolled in AMISTAD, 166 (70 %) with no ECG confounding factors and no prior MI were included in this analysis. Of these, group 1 (126 patients, 53%) had final infarct size (FIS) available by both ECG and SPECT. Group 2 (56 patients, 24%) had myocardium at risk, FIS, and salvage index (SI) assessed by both SPECT and ECG techniques. Aldrich/Clemmensen scores for myocardium at risk and the Selvester QRS score for final MI size were used. Salvage index was calculated as follows: SI = (myocardium at risk−FIS)/(myocardium at risk).

Results

In group 1, FIS was 15% (6, 24) as measured by ECG and 11% (2, 27) as measured by SPECT. In the adenosine group, FIS was 12% (6, 21) and 11% (2, 22). In the placebo group, FIS was 16.5% (7.5, 24) and 11.5% (3.0, 38.5) by ECG and SPECT, respectively. The overall correlation between SPECT and ECG for FIS was 0.58 (P = .0001): 0.60 in the placebo group (P = .0001) and 0.54 (P = .0001) in the adenosine group. In group 2, myocardium at risk was 23% (17, 30) and 26% (10, 50) with ECG and SPECT, respectively (P = .0066). Final infarct size was 17% (6, 21) and 12% (1, 24) (P < .0001). The SI was 29% (-7, 57) and 46% (15, 79) with ECG and SPECT, respectively (P = .0510).

Conclusions

The ECG measurement of infarct size has a moderate relationship with SPECT infarct size measurements in the population with available assessments. This ECG algorithm must further be validated on clinical outcomes.